Tel/PDGFRβ induces stem cell differentiation via the Ras/ERK and STAT5 signaling pathways

Experimental Hematology

Volumn 37, Issue 1, 2009, Pages

  Dobbin, Edwina ^a   Graham, Ciaren ^a   Corrigan, Pamela M ^a   Thomas, Keith G ^a   Freeburn, Robin W ^a   Wheadon, Helen ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; MUTANT PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE; RAS PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; TETRACYCLINE; TRANSCRIPTION FACTOR ETV6; ONCOPROTEIN; REPRESSOR PROTEIN; STAT3 PROTEIN, MOUSE; TRANSCRIPTION FACTOR ETS; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL RENEWAL; CONTROLLED STUDY; EMBRYONIC STEM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; MOUSE; MYELOPOIESIS; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; WILD TYPE; ANIMAL; CANCER STEM CELL; CELL LINE; CHRONIC MYELOID LEUKEMIA; GENETICS; HUMAN; METABOLISM; PATHOLOGY;

MUS;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CELL DIFFERENTIATION; CELL LINE; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MAP KINASE SIGNALING SYSTEM; MICE; NEOPLASTIC STEM CELLS; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEINS C-ETS; RAS PROTEINS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; REPRESSOR PROTEINS; STAT3 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR;

EID: 57549095434     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2008.09.012     Document Type: Article

References (43)

1. Jaffe E.S., Harris N.L., Stein H., and Vardiman J.W. World Health Organization of Tumours: Pathology and Genetics. Tumours of Haematopoietic and Lymphoid Tissues (2001), IARC Press, Lyon, France p. 17-59
2. Tefferi A., and Vardiman J.W. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22 (2008) 14-22
3. Shtivelman E., Lifshitz B., Gale R.P., and Canaani E. Fused transcript of Abl and Bcr genes in chronic myelogenous leukemia. Nature 315 (1985) 550-554
4. Levine R.L., Pardanani A., Tefferi A., and Gilliland D.G. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 7 (2007) 673-683
5. Tefferi A., and Gilliland D.G. Oncogenes in myeloproliferative disorders. Cell Cycle 1 6 (2007) 550-566
6. Golub T.R., Barker G.F., Lovett M., and Gilliland D.G. Fusion of PDGF receptor [beta] to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77 (1994) 307-316
7. Carroll M., Tomasson M.H., Barker G.F., Golub T.R., and Gilliland D.G. The TEL/platelet-derived growth factor beta receptor (PDGFbeta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGFbeta R kinase-dependent signaling pathways. Proc Natl Acad Sci U S A 93 (1996) 14845-14850
8. Tomasson M.H., Sternberg D.W., Williams I.R., et al. Fatal myeloproliferation, induced in mice by TEL/PDGFbetaR expression, depends on PDGFbetaR tyrosines 579/581. J Clin Invest 105 (2000) 423-432
9. Dierov J., Xu Q., Dierova R., and Carroll M. TEL/platelet-derived growth factor receptor beta activates phosphatidylinositol 3 (PI3) kinase and requires PI3 kinase to regulate the cell cycle. Blood 99 (2002) 1758-1765
10. Wilbanks A.M., Mahajan S., Frank D.A., Druker B.J., Gilliland D.G., and Carroll M. TEL/PDGF[beta]R fusion protein activates STAT1 and STAT5: a common mechanism for transformation by tyrosine kinase fusion proteins. Exp Hematol 28 (2000) 584-593
11. Wheadon H., and Welham M.J. The coupling of TEL/PDGF{beta}R to distinct functional responses is modulated by the presence of cytokine: involvement of mitogen-activated protein kinases. Blood 102 (2003) 1480-1489
12. Cain J.A., Xiang Z., O'Neal J., et al. Myeloproliferative disease induced by TEL-PDGFRβ displays dynamic range sensitivity to STAT5 gene dosage. Blood 109 (2007) 3906-3914
13. Valgeirsdottir S., Paukku K., Silvennoinen O., Heldin C.H., and Claesson-Welsh L. Activation of STAT5 by platelet-derived growth factor (PDGF) is dependent on phosphorylation sites in PDGF beta-receptor juxtamembrane and kinase insert domains. Oncogene 16 (1998) 505-515
14. Jousset C., Carron C., Boureux A., et al. A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL-PDGFR beta oncoprotein. EMBO J 16 (1997) 69-82
15. Dobbin E., Corrigan P.M., Walsh C.P., Welham M.J., Freeburn R.W., and Wheadon H. Tel/PDGFR[beta] inhibits self-renewal and directs myelomonocytic differentiation of ES cells. Leukemia Res 32 (2008) 1554-1564
16. Paling N.R.D., Wheadon H., Bone H.K., and Welham M.J. Regulation of embryonic stem cell self-renewal by phosphoinositide 3-kinase-dependent signaling. J Biol Chem 279 (2004) 48063-48070
17. Matsuda T., Nakamura T., Nakao K., et al. Stat 3 activation is sufficient to maintain an undifferentiated state of embryonic stem cells. EMBO J 18 (1999) 4261-4269
18. Niwa H., Burdon T., Chambers I., and Smith A. Self-renewal of embryonic stem cells is mediated via activation of Stat3. Genes Dev 12 (1998) 2048-2060
19. Nemetz C., and Hocke G.M. Transcription factor STAT5 is an early marker of differentiation of murine embryonic stem cells. Differentiation 62 (1998) 213-220
20. Burdon T., Stracey C., Chambers I., Nichols J., and Smith A. Suppression of SHP-2 and ERK signalling promotes self-renewal of mouse embryonic stem cells. Dev Biol 210 (1999) 30-43
21. Duval D., Malaise M., Reinhardt B., Kedinger C., and Boeuf H. A p38 inhibitor allows to dissociate differentiation and apoptotic processes triggered upon LIF withdrawal in mouse embryonic stem cells. Cell Death Differ 11 (2004) 331-341
22. Ernst M., Oates A., and Dunn A.R. gp130-Mediated signal transduction in embryonic stem cells involves activation of Jak and Ras/mitogen-activated protein kinase pathways. J Biol Chem 271 (1996) 30136-30143
23. Nichols J., Zevnik B., Anastassiadis K., et al. Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Cell 3 (1998) 379-391
24. Bashamboo A., Taylor A.H., Samuel K., Panthier J.J., Whetton A.D., and Forrester L.M. The survival of differentiating embryonic stem cells is dependent on the SCF-KIT pathway. J Cell Sci 119 (2006) 3039-3046
25. Lengerke C., McKinney-Freeman S., Naveiras O., et al. The Cdx-Hox pathway in hematopoietic stem cell formation from embryonic stem cells. Ann N Y Acad Sci 1106 (2007) 197-208
26. Friedman A.D. Transcriptional control of granulocyte and monocyte development. Oncogene 26 (2007) 6816-6828
27. Matsuda T., Nakamura T., Nakao K., et al. STAT3 activation is sufficient to maintain an undifferentiated state of mouse embryonic stem cells. EMBO J 18 (1999) 4261-4269
28. Nima H., Burdon T., Chambers I., and Smith A. Self-renewal of pluripotent embryonic stem cells is mediated via activation of STAT3. Genes Dev 12 (1998) 2048-2060
29. Cartwright P., McLean C., Sheppard A., Rivett D., Jones K., and Dalton S. LIF/STAT3 controls ES cell self-renewal and pluripotency by a Myc-dependent mechanism. Development 132 (2005) 885-896
30. Yates A., and Chambers I. The homeodomain protein Nanog and pluripotency in mouse embryonic stem cells. Biochem Soc Trans 33 (2005) 1518-1521
31. Ying Q.L., Nichols J., Chambers I., and Smith A. BMP induction of Id proteins suppresses differentiation and sustains embryonic stem cell self-renewal in collaboration with STAT3. Cell 115 (2003) 281-292
32. Coppo P., Dusanter-Fourt I., Millot G., et al. Constitutive and specific activation of STAT3 by BCR-ABL in embryonic stem cells. Oncogene 22 (2003) 4102-4110
33. Wheadon H., Roberts P.J., Watts M.J., and Linch D.C. Changes in signal transduction downstream from the granulocyte-macrophage colony-stimulating factor receptor during differentiation of primary hemopoietic cells. Exp Hematol 27 (1999) 1077-1086
34. Yuo A. Differentiation, apoptosis, and function of human immature and mature myeloid cells: intracellular signaling mechanism. Int J Hematol 73 (2001) 438-452
35. Steinberg M. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Ther 29 (2007) 2289-2308
36. Apperley J.F., Gardembas M., Melo J.V., et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 347 (2002) 481-487
37. Lu M., Glover C.H., Tien A.H., et al. Involvement of tyrosine kinase signaling in maintaining murine embryonic stem cell functionality. Exp Hematol 35 (2007) 1293-1302
38. Hallek M., Danhauser-Riedl S., Herbst R., et al. Interaction of the receptor tyrosine kinase p145c-kit with the p210bcr/abl kinase in myeloid cells. Br J Haematol 94 (1996) 5-16
39. Pierce A., Spooncer E., Ainsworth S., and Whetton A.D. BCR-ABL alters the proliferation and differentiation response of multipotent hematopoietic cells to stem cell factor. Oncogene 21 (2002) 3068-3075
40. Wong S., McLaughlin J., Cheng D., Zhang C., Shokat K.M., and Witte O.N. Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations. Proc Natl Acad Sci U S A 101 (2004) 17456-17461
41. Inokuchi K., Yamaguchi H., Tarusawa M., et al. Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia-potential clinical significance. Leukemia 16 (2002) 170-177
42. Feldman E.J. Farnesyltransferase inhibitors in myelodysplastic syndrome. Curr Hematol Rep 4 (2005) 186-190
43. Gotlib J. Farnesyltransferase inhibitor therapy in acute myelogenous leukemia. Curr Hematol Rep 4 (2005) 77-84